About: BCL‐6 Prevents Mammary Epithelial Apoptosis, Promotes Cell Survival and is Expressed in Breast Carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: BCL‐6 Prevents Mammary Epithelial Apoptosis, Promotes Cell Survival and is Expressed in Breast Carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	BCL‐6 Prevents Mammary Epithelial Apoptosis, Promotes Cell Survival and is Expressed in Breast Carcinoma
Creator	Thiel, Steffen Astrinidou-Vakaloudi, A Diamanti, I Georgakopoulou, E Hans, Reinholdt Hoffmann, Jürgen Jesper, Ralf Xatzidimitriou, D Xytsas, S
Source	PMC
abstract	Background: Proliferation, differentiation and apoptosis are essential processes in the normal functions of the mammary epithelium. The hypothesis examined in this study is that the transcription factor BCL‐6 is critically important not only for regulating B‐cell growth and development but also for mammary epithelial apoptosis. Methodology: Twenty breast cancer cases and 31 healthy controls were used to investigate whether BCL‐6 protein in involved in breast cancer (grade III). Full length BCL‐6 cDNA was retrovirally transduced into EpH‐4 cell line. We then used flow cytometry of BrdUrd‐stained cells to investigate the cell‐cycle duration of the control and transduced cell lines. TUNEL was used as a marker of apoptosis to find out differences in the frequencies of apoptotic cells in the control and transduced cell lines. Finally, immunohistochemistry staining was performed to detect BCL‐6 in breast cancer (III). Results: Restoration of BCL‐6 into EpH‐4 cells not only inhibits apoptosis but also prolongs the cell cycle and results in increased cell size and protein content. The results also indicated that the cell‐cycle time of BCL‐6‐transduced EpH‐4 cells is prolonged by about 3 h, presumably as a result of the action of BCL‐6 at the BCL‐6 at the G1/S transition. We found differences in the frequencies of viable and apoptotic cells in cultures of the parent EpH‐4 cells, control‐transduced EpH‐4 cells and BCL‐6‐transduced EpH‐4 cells. Consistently, we demonstrated that BCL‐6 is expressed in 90% of high grade of breast carcinoma, which is considered as the most aggressive of tumours. Conclusion: Together, these results suggest that BCL‐6 is likely to be involved in mammary gland development and carcinogenesis.
has issue date	2008-06-28(xsd:dateTime)
bibo:doi	10.1111/j.0300-9475.2004.01423bh.x
has license	no-cc
sha1sum (hex)	47f1e83a120bb84f7cbb95319be9fb47a4c885fd
schema:url	https://doi.org/10.1111/j.0300-9475.2004.01423bh.x
resource representing a document's title	BCL‐6 Prevents Mammary Epithelial Apoptosis, Promotes Cell Survival and is Expressed in Breast Carcinoma
has PubMed Central identifier	PMC7169579
schema:publication	Scand J Immunol
resource representing a document's body	covid:47f1e83a120bb84f7cbb95319be9fb47a4c885fd#body_text
is schema:about of	named entity 'regulatory T cells' named entity 'Trypanosoma brucei' named entity 'antibodies' named entity 'MBL' named entity 'pathogens' named entity 'TGF-b' named entity 'MASPs' named entity 'Antibody' named entity 'MBL' named entity 'vitamins' named entity 'monocytes' named entity 'IFN' named entity 'IFN-g' named entity 'cartilage' named entity 'CRP' named entity 'protein' named entity 'FEV1' named entity 'CD8' named entity 'IFN' named entity 'hepatocellular carcinoma' named entity 'E. coli' named entity 'antibody' named entity 'pro-enzyme' named entity 'control subjects' named entity 'MnSOD' named entity 'myelin basic protein' named entity 'plasma' named entity 'pneumococci' named entity 'immune response' named entity 'IFN-g' named entity 'paraffin' named entity 'parenteral' named entity 'blood donors' named entity 'receptor expression' named entity 'bioinformatics' named entity 'commensal bacteria' named entity 'cutaneous' named entity 'IFN' named entity 'antibody' named entity 'immunomodulating' named entity 'DTH' named entity 'complement' named entity 'phagocytes' named entity 'IL-12' named entity 'gastric juice' named entity 'endogenous' named entity 'binding region' named entity 'HLA' named entity 'TNF-a' named entity 'oxazolone' named entity 'macrophages' named entity 'citrulline' named entity 'Lactobacillus paracasei' named entity 'transcriptional regulators' named entity 'HLA' named entity 'probiotic' named entity 'anti-inflammatory' named entity 'pneumococci' named entity 'oral mucosa' named entity 'mice' named entity 'arginase' named entity 'amino acid residues' named entity 'antigen' named entity 'CD83' named entity 'fusion protein' named entity 'CD69' named entity 'infection' named entity 'TNF-a' named entity 'dermis' named entity 'IFN' named entity 'MSCs' named entity 'Mycobacterial' named entity 'diabetic patients' named entity 'idiotypic' named entity 'Flow cytometry'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software